

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

Phospho-S6 Ribosomal Protein

RRID:AB_331682

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2215, RRID:AB_331682

Antibody Information

URL: http://antibodyregistry.org/AB_331682

Proper Citation: Cell Signaling Technology Cat# 2215, RRID:AB_331682

Target Antigen: Polyclonal antibodies are produced by immunizing animals with a synthetic phospho-peptide (KLH-coupled) corresponding to residues surrounding Ser240 and Ser244 of human S6 ribosomal protein

Host Organism: rabbit

Clonality: unknown

Comments: Applications: W, IP. Consolidation on 11/2018: AB_10078212, AB_2630325, AB_331682, AB_331683. Info: Used By NYUIHC-399.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Phospho-S6 Ribosomal Protein

Description: This unknown targets Polyclonal antibodies are produced by immunizing animals with a synthetic phospho-peptide (KLH-coupled) corresponding to residues surrounding Ser240 and Ser244 of human S6 ribosomal protein

Antibody ID: AB_331682

Vendor: Cell Signaling Technology

Catalog Number: 2215

Record Creation Time: 20231110T044856+0000

Record Last Update: 20260829T024734+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-S6 Ribosomal Protein.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 106 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tsang AH, et al. (2026) Cav3.1 is a neuronal leucine sensor that mediates satiety and weight loss in response to dietary protein. *Cell metabolism*, 38(5), 876.

Han X, et al. (2026) Mechanistic insights into fatty acid odor detection mediated by class II olfactory receptors. *Cell*, 189(5), 1465.

Chen J, et al. (2026) A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1652.

Martín A, et al. (2026) Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. *Cancer research*.

Nagel R, et al. (2026) Arginine Deprivation of ASS1-Deficient Cancers Drives Mistranslation and Shared Neoepitope Production. *Cancer research*, 86(14), 3480.

Shrivastava A, et al. (2026) Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer. *Cell reports*, 45(6), 117520.

Billmann M, et al. (2026) Global genetic interaction network of a human cell maps conserved principles and informs functional interpretation of gene co-essentiality profiles. *Cell*, 189(12), 3736.

Torii S, et al. (2025) Embryological cellular origins and hypoxia-mediated mechanisms in PIK3CA-driven refractory vascular malformations. *EMBO molecular medicine*, 17(6), 1289.

Jackson CB, et al. (2025) De novo serine biosynthesis is protective in mitochondrial disease. *Cell reports*, 44(5), 115710.

Yao Y, et al. (2025) The Cullin3-Rbx1-KLHL9 E3 ubiquitin ligase complex ubiquitinates Rheb and supports amino acid-induced mTORC1 activation. *Cell reports*, 44(1), 115101.

Turnham RE, et al. (2025) HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. *Cancer research*, 85(4), 660.

Pataccini G, et al. (2025) Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country. *Scientific reports*, 15(1), 2415.

Mokhtar N, et al. (2025) 5-HT₆ Receptor Inverse Agonists Modulate Diabetic Neuropathic Pain in Female Rats: Evidence for 5-HT₆ Receptor Constitutive Activity. *Journal of neurochemistry*, 169(8), e70179.

Kahlhofer J, et al. (2025) TXNIP mediates LAT1/SLC7A5 endocytosis to limit amino acid uptake in cells entering quiescence. *The EMBO journal*, 44(23), 7119.

Shin J, et al. (2025) Growth factor-independent mTORC1 signaling promotes primary cilia length via suppression of autophagy. *iScience*, 28(12), 114204.

Cormerais Y, et al. (2025) AKT-mediated phosphorylation of TSC2 controls stimulus- and tissue-specific mTORC1 signaling and organ growth. *Developmental cell*, 60(19), 2544.

Chaouki G, et al. (2025) Pre-cachectic changes in amino acid homeostasis precede activation of eIF2 γ signaling in the liver at the onset of C26 cancer-induced cachexia. *iScience*, 28(3), 112030.

Thalalla Gamage S, et al. (2025) Transfer RNA acetylation regulates in vivo mammalian stress signaling. *Science advances*, 11(12), eads2923.

Varadarajan K, et al. (2025) Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations. *Molecular cancer therapeutics*, 24(9), 1402.

Ikeda T, et al. (2025) HUWE1 stimulates mTORC1 activity by enhancing Rheb interaction with mTORC1 and supports de novo pyrimidine synthesis. *Cell reports*, 44(10), 116382.